{
  "symbol": "SGHT",
  "company": "Sight Sciences, Inc.",
  "generated_at": "2026-06-24T07:36:52.742Z",
  "event_count": 3,
  "events": [
    {
      "type": "pipeline_event",
      "ts": "2026-06-05T21:02:45.691Z",
      "stage": "analyst",
      "outcome": "skip",
      "reason": "Triggered anti-signal gates for going concern, dilution, and accounting flags. The dossier lacks smart-money accumulation, sustained options flow, or quantifiable mispricing to offset the high appellate risk and ongoing cash burn.",
      "trigger": "[insider_cluster_universe] 3 Form 4 filings in last 14 days · at least one open-market P/S trade verified",
      "source": "idle_hunter"
    },
    {
      "type": "analyst_decision",
      "ts": "2026-06-05T21:02:45.673Z",
      "skip": true,
      "reason": "Triggered anti-signal gates for going concern, dilution, and accounting flags. The dossier lacks smart-money accumulation, sustained options flow, or quantifiable mispricing to offset the high appellate risk and ongoing cash burn.",
      "score": 10,
      "breakdown": {
        "smart_money": 0,
        "options_flow": 0,
        "catalyst": 5,
        "mispricing": 0,
        "quality": 0,
        "technical": 5
      },
      "debug_path": "drafts/2026-06-05-SGHT.analyst.debug.json"
    },
    {
      "type": "scout_dossier",
      "ts": "2026-06-05T21:02:11.208Z",
      "summary": "Sight Sciences makes ophthalmic surgical devices for glaucoma (OMNI Surgical System) and dry eye disease (TearCare). The investigation trigger — 3 Form 4 filings in 14 days — was met (June 4-5, 2026), but all three were director RSU grants under the Non-Employee Director Compensation Program at $0.00 price, NOT open-market purchases. This is a critical distinction: the smart-money signal is noise. However, two genuinely material catalysts exist: (1) A March 27, 2026 Delaware federal court ruling preserving a jury verdict of willful patent infringement against Alcon's Hydrus Microstent and awarding $34M in damages plus an ongoing 10% royalty through November 2028 — potentially worth hundreds of millions if collected. (2) Q1 FY26 earnings beat on May 6, 2026 with revenue guidance raised for full-year 2026. The company is deeply unprofitable (forward P/E N/M), burning $7-13M cash per quarter, and the stock trades ~52% below its 52-week high of $9.05. Valuation at current prices reflects substantial skepticism about execution; if the Alcon damages are ultimately collected without reversal on appeal, SGHT's financial trajectory transforms materially.",
      "verdict": "range_bound_or_income",
      "confidence": 4,
      "tool_calls": 20,
      "walltime_min": 19,
      "debug_path": "dossiers/2026-06-05-SGHT.scout.debug.json"
    }
  ],
  "lessons": [],
  "chart_signal": {
    "ticker": "SGHT",
    "call": "HOLD",
    "confidence": 3,
    "score": 4,
    "factors": {
      "above_200dma": "+2",
      "above_50dma": "+1",
      "momentum_up": "+1 (20.7%)",
      "rsi_neutral": "0 (63.8)",
      "macd_above_signal": "+1",
      "recent_macd_bullish_cross": "+1 (6d ago)",
      "broken_below_high": "-2 (-40.2% from high)"
    },
    "summary": "HOLD (score +4) · 12-1 mom 20.7% · RSI 63.8 · above_both · -40.2% from high",
    "last_close": 5.41,
    "one_month_ago_close": 5.14,
    "twelve_month_ago_close": 4.26,
    "twelve_one_momentum_pct": 20.66,
    "rsi_14": 63.8,
    "ma_stack": "above_both",
    "from_period_high_pct": -40.22,
    "period_high": 9.05,
    "price_targets": {
      "bear": 5.15,
      "fair": 6.2,
      "bull": 12,
      "bear_return_pct": -4.8,
      "fair_return_pct": 14.6,
      "bull_return_pct": 121.8,
      "method": "street_targets ⨯ chart_floors",
      "street": {
        "target_low": 5.15,
        "target_mean": 8.5375,
        "target_high": 12,
        "analyst_count": 4
      }
    },
    "generated_at": "2026-06-24T07:36:52.736Z"
  }
}